Orexo (ORX.ST)

Executive Summary

Orexo is a Swedish specialty pharmaceutical company leveraging its proprietary AmorphOX® drug delivery platform to develop improved therapies for severe diseases and rescue medications. The company has built a commercial portfolio anchored by Zubsolv (buprenorphine/naloxone) for opioid dependence, which generates steady revenue. Orexo is also advancing a pipeline targeting opioid overdose reversal (OX124) and opioid use disorder (OX125), with a focus on enhancing bioavailability and patient convenience. The AmorphOX® technology improves solubility and stability of active ingredients, enabling differentiated formulations that could address unmet medical needs in addiction and pain management. With a lean operational structure and a clear strategic focus on central nervous system (CNS) disorders, Orexo is positioned for near-term value creation through regulatory milestones and market expansion.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on OX124 (naloxone nasal spray) for opioid overdose70% success
• Q4 2026Phase 2/3 data readout for OX125 (buprenorphine) for opioid use disorder60% success
• TBDPotential partnership or licensing deal for AmorphOX® platform or pipeline assets50% success